US Kidney Cancer Therapeutics and Diagnostics Market Expected to Reach 3 Bn US$ By 2028: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit The US Kidney Cancer Therapeutics and Diagnostics Market is poised for a steered growth due to rise in cases of kidney cancer, an increase in success rate of targeted therapies, expansion of hospitals and NCI- funded cancer centers, and constant growth in population. Story Outline Rising cases of Kidney Cancer due to today’s drastic lifestyle changes, environmental exposures to certain harmful chemicals, obesity, and poor diet is propelling the growth of US Kidney Cancer Therapeutics and Diagnostics Market. Targeted therapy is emerging as a key therapy to treat kidney Cancer and related diseases. As it directly targets molecular and genetic abnormalities and provides increased success rate and patient satisfaction. Expansion of Hospitals and NCI-funded cancer centers are helping patients to get advanced treatment at affordable rates which is also fueling the growth in the market. Increasing pool of patients is witnessed due to constant growth in the population of US. The rise in patient pool increases the demand for treatment and diagnostics services, resulting in increased demand for innovative technology and treatment advancement, thus fueling the market’s growth. US Kidney Cancer Therapeutics and Diagnostics Market is expected to grow at a CAGR of 5% in the forecast period (2022-2028) and is being driven due to rise in cases of kidney cancer, an increase in success rate of targeted therapies, expansion of hospitals and NCI- funded cancer centers, and constant growth in population. This article will provide information about the growth drivers of the US Kidney Cancer Therapeutics and Diagnostics market in detail. 1. Rising incidence of Kidney Cancer cases is giving US Kidney Cancer Therapeutics and Diagnostics Market a promising growth Click here to read full article: US Kidney Cancer Diagnostics Technology The increasing cases of Kidney Cancer in US is seen as a significant factor in propelling the growth of the Kidney Cancer Therapeutics and Diagnostics Market. The visible rise in Kidney Cancer cases is increasing the demand for advanced solutions. This results in a symbiotic relationship between diversification of patient pool and market’s development. In 2022, out of around a total of 1,918,03 cancer cases of all types approx. 79,000 cases were of kidney cancer (50.290 male 28,710 female), deaths from kidney cancer were around 14,000. According to The American Cancer Society’s recent estimates, in 2023 81,800 adults (52,360 men and 29,440 women) in the United States will be diagnosed with kidney cancer. The total number of deaths is estimated at 14,890 (9,920 men and 4,970 women). In US, kidney cancer is considered the sixth most common cancer in men and the ninth most common cancer in women. The average age at which people are diagnosed with kidney cancer is 64, most of the people diagnosed with kidney cancer are of age between 65 to 74. The average 5-year survival rate for kidney cancer in US is around 77%. Today’s drastic lifestyle changes, environmental exposures to certain harmful chemicals, obesity, and poor diet seem to be the most common reasons for the gradual growth of kidney cancer in today’s world. These lifestyle changes if ignored for a long time, are taking a toll on our health thus increasing the risk and cases of diseases like kidney cancers which propels the growth of Kidney Cancer Therapeutics and Diagnostics Market. 2. Is the success rate of targeted therapy overcoming the demand for other therapies for Kidney Cancer treatment in US? Click here for Download a Free Sample Report Targeted therapies are becoming a pivotal growth driver of the US Kidney Cancer and Therapeutics Market, due to their effectiveness and increased patient satisfaction rate. The targeted therapy specifically targets the underlying molecular and genetic abnormalities that fuel the growth of kidney cancer. By altering the side effects by traditional chemotherapy and delivering improved treatment outcomes. The Cohot study shows that targeted therapy for Kidney cancer or Renal Cell Carcinoma (RCC) has shown increased tolerability and survival rates as compared to non-targeted therapy treatment. Seeing these positive results from targeted therapy, the Food and Drug Administration has approved 12 targeted therapies for the treatment of Kidney cancer since 2005. The continuous growth of targeted therapies’ precision and effectiveness have not only enhanced patient satisfaction but also fostered substantial growth in the US Kidney Cancer and Therapeutics Market. As the research continuous leading to the innovation of new therapies and markets expansion. 3. Expansion of hospitals and NCI-funded cancer centers helping the patients with better treatment opportunities Visit this Link: – Request for custom report The growth of the Kidney Cancer Therapeutics and Diagnostics Market is closely related to the expansion of hospitals and medical centers. They play a critical role in the treatment, diagnosis, and supportive care of the diagnosed patient. There are around 900 hospitals for treating cancer in US. The best cancer hospitals according to US News and World Report in its annual ranking of American Hospitals are, The University of Texas MD Anderson Cancer Center, The Memorial Sloan Kettering Cancer Center, and Mayo Clinic. The US News and World Report ranks hospitals according to the criteria such as 30-day mortality, 30-day readmission, and how long patients tend to stay in hospital. There are around 72 National Cancer Institute (NCI) designated Cancer Centers, located in around 36 states and the District of Columbia, that have met the standard of care according to NC. Out of these 72 institutions, 11 are Cancer Centers, 54 are comprehensive cancer centers, and 7 are basic laboratory cancer centers. These cancer centers are funded by NCI to deliver cutting-edge technology and advanced treatment care to patients. Each year approximately 2,50,000 patients receive their cancer diagnosis at NCI-funded cancer centers and thousands of patients are enrolled in clinical trials for cancer at NCI. These NCI centers also provide public education and outreach campaigns on cancer prevention screening and early diagnosis. These NCI centers have worked hard for decades and have increased the number of cancer survivors in Us and have improved patient’s life immeasurably. The growth of hospitals and cancer centers in US supports Kidney Cancer Therapeutics and Diagnostics Market by improving access to advanced technology diagnostics, and patient care ultimately driving market growth. 4. Constant population growth in US, leading to large patient pool and an increase in need for advanced treatment and diagnostics technologies Request free 30 minutes analyst call An increase in population has continuously contributed to the growth of the Kidney Cancer Therapeutics and Diagnostics Market. As there is a larger pool of potential patients which leads to increased demand for Kidney Cancer and Diagnostics services and treatment options. With a large patient base, pharmaceutical companies and medical product manufacturers are encouraged to invest more in research and development of diagnostic tools and innovative therapies. According to the data the population of US as of 2022, was approx. 336 million; and around 330 million in 2021. The population growth rate of US in 2022 was around 0.38% as compared to the growth rate in 2021 at around 0.30%. As of 2023, the growth rate is 0.50%. A larger population allows a broader recruitment pool for clinical trials too, enabling the validation of new treatment modes. Overall, the expanding population is not only driving the growth of US Kidney Cancer Therapeutics and Diagnostics Market but also fuels innovation in the market at a continuous level. Conclusion The escalating cases of kidney cancer in the US have created a dynamic synergy that drives the growth of the Kidney Cancer Therapeutics and Diagnostics Market. The visible rise in cases intensifies the demand for advanced solutions, spurring investment in research and development. Targeted therapies emerge as a game-changer, offering precision and effectiveness, while the expansion of hospitals amplifies patient access to cutting-edge diagnostics and treatments. With a steadily increasing population contributing to a larger patient base, pharmaceutical advancements, and research collaboration thrive. As the market evolves to meet these challenges, it stands poised for continuous development, bolstered by innovations that improve patient outcomes and redefine the landscape of kidney cancer care. Tags: Acute Leukemia Market Growth US, Amgen Inc. Kidney Cancer Treatment Market Size, Bayer Kidney Cancer Treatment Market Size, Bristol Myers Squibb Kidney Cancer Therapeutics Market Size, Emerging Players Kidney Cancer Diagnosis Market, F. Hoffmann Kidney Cancer Diagnostics Revenue, Fund Raised Startups Kidney Cancer therapy Sector US, Investment US Kidney Cancer Diagnostics Market, Kidney Cancer Diagnostics Companies US, Kidney Cancer Diagnostics Sector Challenges US, Kidney Malignancy Therapy Market US, Kidney Neoplasm Treatment Industry US, Kidney Tumor Treatment and Diagnosis Market US, Major Competitor US Renal Cancer Treatment Market, Major Players US Kidney Cancer Therapy Market, Nephrological Tumor Treatment and Testing Market US, Novartis AG Kidney Cancer Therapeutics Market Share, Number of Renal Cancer Diagnosis US, Pfizer Kidney Cancer Therapeutics Market Revenue, Top 5 Funded Kidney Cancer Treatment Companies US, Top Players US Kidney Cancer Diagnostics Market, United States Kidney Cancer Therapeutics Market, US Kidney Cancer Detection Market, US Kidney Cancer Diagnostics Centers, US Kidney Cancer Diagnostics Industry, US Kidney Cancer Diagnostics Market, US Kidney Cancer Therapeutics and Diagnostics Industry, US Kidney Cancer Therapeutics and Diagnostics Market, US Kidney Cancer Treatment Market, US Kidney Carcinoma Diagnosis Industry, US Kidney Carcinoma Treatment Market Trends, US Kidney Neoplasm Therapy and Testing Market, US Kidney Tumor Treatment Market, US Pharmaceutical and Biotech Companies, US Renal Cancer Treatment Market Challenges, US Renal Cell Carcinoma Care and Diagnosis Market, US Renal Cell Carcinoma Screening Sector, US Renal Cell Carcinoma Treatment Market, US Top Diagnostics Companies